Literature DB >> 11069320

Identifying responders to acid suppression in dyspepsia using a random starting day trial.

P Bytzer1, J M Hansen, S Rune, O Bonnevie, H Breinstrup, P Funch-Jensen, P Matzen, V Meineche-Schmidt, O B Schaffalitzky De Muckadell.   

Abstract

BACKGROUND: Functional dyspepsia is a heterogeneous condition and a uniform response to drug treatment is not likely. This may be the reason for the general failure of acid suppression in clinical trials in these patients. It may be more rewarding to identify true responders to drug treatment by a single subject trial. AIM: To develop and to test a novel single subject trial design (random starting day trial) in dyspeptic patients. PATIENTS AND METHODS: A total of 301 dyspeptic patients entered a 16-day trial. All patients received placebo for the first 4 days and switched to omeprazole at a randomized and blinded day between day 5 and day 14. Response was defined as a sustained >/= 50% decrease in symptom score occurring in relation to drug shifting.
RESULTS: Spontaneous response varied between 0.3% and 10.6% per day, uniformly distributed over time. Overall, 53-61% of patients with organic dyspepsia had a symptom response in relation to shifting to active treatment, compared to only 23% of patients with functional dyspepsia. The only predictor of response was symptoms suggesting gastro-oesophageal reflux.
CONCLUSIONS: A random starting day trial may be a valuable tool to identify response to acid suppression in dyspeptic patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11069320     DOI: 10.1046/j.1365-2036.2000.00866.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  2 in total

Review 1.  Drug treatment of functional dyspepsia.

Authors:  Klaus Mönkemüller; Peter Malfertheiner
Journal:  World J Gastroenterol       Date:  2006-05-07       Impact factor: 5.742

Review 2.  Proton pump inhibitors for functional dyspepsia.

Authors:  Maria Ines Pinto-Sanchez; Yuhong Yuan; Ahmed Hassan; Premysl Bercik; Paul Moayyedi
Journal:  Cochrane Database Syst Rev       Date:  2017-11-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.